Spica Therapeutics Closes €10 Million Seed Round to Advance Macrophage-Targeted Therapies
The financing round was co-led by Bioqube Ventures and Flanders Future Tech Fund (FFTF, managed by the Flemish investment company PMV), with participation from Qbic. Spica entered a strategic collaboration with Vrije Universiteit Brussel (VUB) and VIB, a leading life sciences research institute to leverage world-class expertise across Belgium. The funding will enable the company […]
Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held from May 30 to June 3, 2025, at the McCormick Place in Chicago, IL. The poster […]
SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)
SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab for the treatment of TGCT patients that are not amenable to or who would not benefit from surgery. […]
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual Meeting (AACR) 2025 being held in Chicago April 25-30, 2025. In the poster, entitled “Preferential tumor uptake and retention of EGL-001, an anti-CTLA4-IL2 mutein fusion […]
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today […]
Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative. Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, […]
Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform
Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5m Funds will be used to further develop Commit’s BiCE platform and move towards drug candidate (DC) selection Eva Van Overmeire, Senior Investment Manager at Korys, also joins Commit’s Board of Directors Mikkel Wandahl Pedersen appointed […]
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer
Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise […]
Bioqube Ventures Unveils Spica Therapeutics to Pioneer Macrophage-Subset Targeted Therapies
Innovating macrophage-targeted therapeutics across multiple therapeutic areas Proprietary functional macrophage fingerprinting technology identifies disease-relevant macrophage subsets Strengthened by the appointments of James Rush as CEO and Jim Van heusden as Chairman Powered by Bioqube Ventures’ venture creation model Spica Therapeutics (“Spica”), a pioneering biotech company focused on macrophage biology, today announced its emergence from stealth mode, supported by […]
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
Appointment solidifies company’s growing US presence. CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. He takes the helm as CatalYm enters a new stage of corporate […]